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The proposed study is a pre and post treatment study to determine whether commonly used 
laxative-treatment for clozapine-treated psychiatric inpatients affects gastrointestinal motility (as 
measured by radiopaque marker (ROM) transit studies). This is a follow up study to the ‘Colonic 
transit studies to measure gastrointestinal motility in antipsychotic-treated patients’ study 




1: RESEARCH QUESTION AND BACKGROUND 
 
Research Questions 
The objective is to determine in a naturalistic setting whether commonly used laxative-treatment 
for clozapine-treated psychiatric inpatients affects gastrointestinal motility when measured 
objectively by radiopaque marker transit studies.  
We will re-measure the gastrointestinal transit times of clozapine-treated participants from our 
first radiopaque marker transit study after they have received at least two months treatment with 
docusate & senna and/or macrogol 3350 (prescribed according to the Porirua Protocol, see below) 
and will compare pre and post laxative transit times. 
 
Background 
Clozapine is an effective agent in the treatment of otherwise treatment-resistant schizophrenia, 
but its adverse effect profile is considerable. Gastrointestinal hypomotility is one commonly 
reported and potentially serious adverse effect. The exact mechanism by which clozapine alters 
colonic functioning have yet to be elucidated. This is usually considered to be anticholinergic 
inhibition of gastrointestinal smooth muscle contraction and peristalsis (e.g. [1], [2]), but it is likely 
that clozapine’s antagonism of various serotonin receptor subtypes compounds the problem [3] as 
serotonin plays a crucial role in gastrointestinal motility [4].  
It has been hypothesised that clozapine use results in increased gastrointestinal transit time –
clozapine induced gastrointestinal hypomotility- associated with accumulation of faeces within the 
bowel and prolonged time between bowel movements [3]. Constipation is reported in up to 60% 
of clozapine-treated patients [6] and in up to 50% of patients treated with other antipsychotics [2]. 
Symptoms of slow transit constipation include low stool frequency, lack of urge to defecate, 
abdominal distension, bloating, and abdominal discomfort [5]. 
 
Clozapine-treated patients with serious gastrointestinal hypomotility often under-report 
symptoms, present late and fatal outcomes have been reported. Progression from constipation to 
ileus, intestinal obstruction, bowel ischaemia, megacolon and death have occurred in this cohort 
[3, 7-12]. In New Zealand over the last decade at least 36 patients have developed life threatening 
gastrointestinal motility problems related to clozapine of whom a number have died. Some of 
these patients were in their twenties with no other comorbidities. 
To date, there is little evidence-based research on the management of gastrointestinal 
hypomotility in antipsychotic-treated patients. Although guidance exists to minimise clozapine’s 
adverse haematological [13, 14], metabolic [15] and cardiac effects [16], these guidelines do not 
emphasise the need to monitor (or treat constipation) and its more serious sequelae. It is not 
known which treatments, if any, are effective in treating clozapine-induced gastrointestinal 
hypomotility. In the service where this research will occur, the Porirua Protocol for preventing and 
treating clozapine associated constipation is used. This protocol involves monitoring 
gastrointestinal function and prescribing docusate and senna in increasing doses up to four tablets 
daily, augmented by macrogol 3350 where necessary. While anecdotally the results of this 
intervention are promising, no study has investigated the outcomes with respect to change in 
transit time, symptoms and serious life threatening sequelae. 
RESEARCH DESIGN AND METHODS  
 
Participants:   
Participants will be recruited from a cohort residing in New Zealand forensic and rehabilitation 
inpatient service who have participated in the first ROM gastrointestinal transit time study 
(currently recruiting) and are prescribed clozapine. None of the participants in the first study will 
have received laxative treatment at the time their gastrointestinal motility was first measured. Up 
to 20 patients will be recruited.  If more than 20 clozapine treated participants participate in the 
first study, participants will be approached in order determined by a random number generator in 
order to randomly select 20 from the original cohort. 
 
 
Inclusion criteria: Male and female adult patients (>18) prescribed clozapine (any dose), who 
participated in the first study, and who are able to provide informed consent and who have 
received laxatives for at least two months.  
 
Exclusion criteria: Patients under the age of 18, unable to provide informed consent or who do not 
understand English will be excluded.  
 
Only patients competent to provide informed consent will be recruited (capacity will be assessed 
by the researchers and checked with the treating psychiatrist). The informed consent form and 
patient information sheets are available from the researchers on request. 
 
Ethical approval: 
The research proposal has been reviewed by the Central Health and Disability Ethics Committee 
and has full ethics approval (reference 13/CEN/153). Consultation with Ngai Tahu has been 
undertaken through the University of Otago and approval given. Consultation with consumer 
consultants has occurred. Capital and Coast District Heath Board has granted site approval. 
Recruitment: 
Recruitment is planned to commence in November 2014 on and continue until all eligible 




No similar studies have been conducted, making power calculations speculative. At alpha=0.05 
and beta=0.8, a sample size of 20 is adequately powered to detect a difference between two 
dependent means (pre and post treatment transit times) of >10 hours (SD=15). It is possible this 
study may be underpowered to detect a true difference, but it will serve to inform future studies.  
 
Process: 
The methodology is pre –specified in detail in the Investigators’ Handbook. A researcher will 
initially spend approximately half an hour with each potential participant explaining the project 
and consenting the patient. The investigator will provide information sheets, which are also 
suitable for low levels of literacy, reading out the material, answering any questions and leaving a 
copy with the potential participant. Participants will be familiar with the methodology, as they will 
be recruited from a cohort who participated in the earlier study. 
 
If the participant provides informed consent they will be recruited into the study, with 
gastrointestinal motility testing occurring the following week. Each participant will participate in 
the study for 4-7 days. All treatment will continue as usual. 
 
The participant will be asked to swallow a small capsule containing ROMs on three consecutive 
days. ROMs are a simple, reliable method of measuring gastrointestinal motility [17]. Using the 
‘Metcalf’ segmental method, the amount of time that the ROMs take to pass through each section 
of the intestinal tract can be tracked [17, 18]. The methodology will be identical to that pre-
laxative gastrointestinal motility test. At the same time on day 1, day 2, and day 3, the participants 
will swallow a soft gelatin capsule contain 24 ring-shaped (4.5 x 1.0 mm) radiopaque markers 
made of polychlorinated vinyl with 33% barium sulphate (sitzmarks). These are tasteless and are 
 
taken by mouth with water. On day four (t= 72 hours), participants will undergo radiological 
imaging to determine the location and extent of elimination of the ROMs. If more than two-thirds 
of ROMs are retained (n=48), abdominal X-ray will be repeated on day 7. The total number of 
markers in each segment will be used to determine transit time. Transit times will be compared 
with population normative values (from meta-analysis of data from healthy controls).  
 
The researchers have chosen to use ROM method for studying gastrointestinal motility despite 
some limitations and drawbacks including radiation exposure (abdominal X-ray). The alternatives 
are scintigraphy (also involving radiation) and a newer technique using a wireless motility capsule 
both of which are considerably more expensive and not currently readily available or logistically 
possible for our population of interest. 
 
For consistency all the X-rays will be read independently by SEP then by senior radiologist MN 
(who will be blinded to clinical and demographic factors). The rectosigmoid will be defined by 
oblique lines between the fifth lumbar vertebra spinous process and the femoral head. Any 
disagreements will be resolved by consensus. 
 





where ∆t = mean transit time, T = time interval between X-rays, N = number of ingested markers, j = number of X-rays taken, and ni = total number 
of markers present on a given film sector. 
 
On day four participants will be screened for constipation, firstly by being asked if they consider 
themselves constipated (‘self-reported constipation’), which is intended to mirror normal clinical 
practice, and secondly by completing a researcher-assisted questionnaire incorporating all Rome 
III constipation symptoms, available on request from the authors. 
 
Demographic and clinical data will be collected on all participants including age, gender, ethnicity, 
diagnoses, smoking status, height and weight and over-the-counter and prescribed medication. 
 
Main Outcome measures: 
We will compare pre and post laxative treatment colonic transit times. 
 
Primary outcome measure: changes in colonic motility times, including segmental transit times 
(right colon, left colon and rectosigmoid transit times) as measured by ROMs (Metcalf technique) 
 
Continuous and categorical outcomes will be reported (i.e. both transit time in hours, and the 
proportion of patients diagnosed with gastrointestinal hypomotility.) Cut-off points for ‘abnormal’ 
motility tests are derived from meta-analysis of normative data in healthy controls and set at 2SD 
above the population mean (i.e. colonic transit time of 65 hours or more). Transit times 4SD above 
the population mean will be considered severe colonic hypomotility. 
 
Secondary outcome measure: subjective symptoms of constipation including self reported 
constipation and a modified ROME III questionnaire. Adverse effect data will also be collected. 
 
 
Data Analysis:  
A biostatistician (JS) is consulting on the statistical analysis for this project.  
 
Descriptive statistics (frequencies with confidence intervals, means with standard deviations) will 
provide data summaries for bowel transit times.  
 
We will use survival analysis to compare continuous outcomes (colonic transit times) and 
McNemar’s test to compare categorical outcomes (proportion of patients with gastrointestinal 
motility and severe gastrointestinal hypomotility.) 
 
Linear and logistic regression methods will then be used to examine which factors are associated 
with the different transit times (age, sex, laxative type and dose).  
 
For hypothesis tests, differences will be considered statistically significant when P<0.05.  
 
Funding: 
This research is supported by a Capital and Coast District Heath Board small research grant. The 
District Health Board is the statutory entity that owns and funds the public hospital in which this 
research will take place. 
 
Dissemination of scientific findings: 
Data will be analysed and a paper reporting the results will be submitted to a high quality peer-
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